Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
DIVISLAB.NS
BuyPremium GrowerDivi's Laboratories Limited · Healthcare · India · $26.8B · Avg Vol: $51M/d
73
StockRankGet insider-trade alerts
Q
76
V
8
M
84
P/E (TTM)
86.2x
ROE
15.3%
D/E
0.0x
Dividend %
0.3%
COMPANY DESCRIPTION
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 76.7B | 78.0B | 93.3B | 104.8B | 11.0% | 112.7B | 124.7B | 148.7B | 19.1% |
| EPS (INR) | 68.69 | 60.27 | 82.53 | 96.75 | 12.1% | 110.49 | 120.61 | 147.26 | 23.4% |
| Shares | 265.5M | 265.5M | 265.5M | 265.5M | 0.0% | 265.5M | — | — | — |
| Debt | 40.0M | 30.0M | 40.0M | 70.0M | 20.5% | 70.2M | — | — | — |
| Equity | 127.7B | 135.7B | 149.7B | 167.6B | 9.5% | — | — | — | — |
| Op CF | 24.6B | 12.6B | 16.5B | 27.4B | 3.6% | 27.5B | — | — | — |
| Inv CF | -27.1B | -2.7B | -8.0B | -22.2B | — | — | — | — | — |
| Fin CF | -8.0B | -8.0B | -8.0B | -8.0B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+21.1%
SMA 50SMA 200
Close
$99.42
RSI (14)
70.9
52W High
$100.75
From 52W High
1.0%
SCORE BREAKDOWN
Quality
76
ROIC
19.0%89.3
ROE
15.3%82.3
GP/Assets
34.3%70.2
Op. Margin
36.7%95.7
FCF/Assets
1.1%50.9
Piotroski
549.3
Int. Cover
50.0x89.2
D/E Ratio
0.00x95.0
Current Ratio
5.43x74.4
Value
8
P/E (TTM)
86.2x10.8
EV/EBITDA
63.3x8.9
P/FCF
1169.7x1.7
P/B
15.0x7.7
P/S
22.4x14.9
Div Yield
0.3%9.2
Momentum
84
52W High %
99%98.8
RS 6M
54%91.7
SMA 50/200
1.19x87.1
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+37%46.1
Q Growth
66%78.2
FUNDAMENTALS
Market Cap
$26.8B
P/E (Forward)
63.1x
Gross Margin
61.2%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DIVISLAB.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DIVISLAB.NS | Divi's Laboratories Limited(you) | $26.8B | 73 | Buy |
| SUNPHARMA.NS | Sun Pharmaceutical Industries Limited | $47.7B | 78 | Buy |
| LAURUSLABS.NS | Laurus Labs Limited | $11.1B | 75 | Buy |
| ZYDUSLIFE.NS | Zydus Lifesciences Limited | $12.1B | 68 | Buy |
| CIPLA.NS | Cipla Limited | $11.8B | 68 | Buy |
| MANKIND.NS | Mankind Pharma Limited | $10.1B | 69 | Buy |
| TORNTPHARM.NS | Torrent Pharmaceuticals Limited | $19.9B | 52 | Hold |
| ALKEM.NS | Alkem Laboratories Limited | $6.5B | 69 | Buy |
| ABBOTINDIA.NS | Abbott India Limited | $5.7B | 79 | Buy |
| AUROPHARMA.NS | Aurobindo Pharma Limited | $10.3B | 91 | Strong Buy |
Peer medians: ROE 11.8% · P/E 42.5x · Gross margin 59.4%